ArticleHepatobiliary surgery and nutrition2018
The SIRveNIB and SARAH trials, radioembolization
Article in Hepatobiliary surgery and nutrition, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- Voxel-based dosimetry for predicting treatment response to transarterial radioembolization in hepatocellular carcinoma: significance of intratumoral dose distribution.EJNMMI physics · 2025Article
- Radioembolization in Hepatocellular Carcinoma: Indications and Outcomes.Journal of gastrointestinal cancer · 2025Review
- Article
- Measure ofEJNMMI reports · 2024Article
- Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Contemporary applications of Y90 for the treatment of hepatocellular carcinoma.Hepatology communications · 2023Article
- The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021.Hepatobiliary surgery and nutrition · 2023Review
- Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.JHEP reports : innovation in hepatology · 2023Article
- Target Trial Emulation: A Design Tool for Cancer Clinical Trials.JCO clinical cancer informatics · 2023Article
- Improved Survival after Transarterial Radioembolisation for Hepatocellular Carcinoma Gives the Procedure Added Value.Journal of clinical medicine · 2022Article
- Radioembolization of Hepatocellular Carcinoma withCancers · 2022Article
- Review
- Beyond the MAA-Y90 Paradigm: The Evolution of Radioembolization Dosimetry Approaches and Scout Particles.Seminars in interventional radiology · 2021Review
- Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons.World journal of gastroenterology · 2021Review
- Management of Liver Tumors during the COVID-19 Pandemic: The Added Value of Selective Internal Radiation Therapy (SIRT).Journal of clinical medicine · 2021Article
- Transarterial Radioembolization for Hepatocellular Carcinoma with Major Vascular Invasion: A Nationwide Propensity Score-Matched Analysis with Target Trial Emulation.Journal of vascular and interventional radiology : JVIR · 2021Article
- Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2021Review
- Effects of Trial Population Selection on Quality of Life and Healthcare Decision-Making: A Systematic Review and Example in the Treatment of Hepatocellular Carcinoma with Radioembolization.ClinicoEconomics and outcomes research : CEOR · 2021Review
- Expression and Prognostic Role of E2F2 in Hepatocellular Carcinoma.International journal of general medicine · 2021Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.